|
|
||||||||
From the Max Planck Institute of Psychiatry, Neurology, Muenchen, Germany.
Address correspondence and reprint requests to Dr. Florian Then Bergh, Neurologische Klinik, Klinikum Grosshadern, Marchioninistr. 15, D-81377 Muenchen, Germany.
OBJECTIVE: To investigate whether dysregulation of the hypothalamopituitaryadrenal (HPA) axis is related to clinical characteristics in MS.
METHODS: The authors performed the combined dexamethasonecorticotropin-releasing hormone test (Dex-CRH test) in 60 MS patients and 29 healthy control subjects. In addition, the short adrenocorticotropic hormone (ACTH) test was performed in 39 consecutive patients. All patients had active disease and none were treated with glucocorticoids, immunosuppressants, or immunomodulators.
RESULTS: The patients had an exaggerated rise in plasma cortisol concentrations in the Dex-CRH test (p < 0.05), indicating hyperactivity of the HPA system. The degree of hyperactivity was moderate in relapsingremitting MS patients (n = 38; area under the time-course curve for cortisol [AUC-Cort] 226.2 ± 38.9 arbitrary units [AU], mean ± SEM), intermediate in secondary progressive MS patients (n = 16; AUC-Cort, 286.8 ± 60.2 AU), and marked in primary progressive MS patients (n = 6; AUC-Cort, 670.6 ± 148.6 AU). Differences were significant between the three patient groups (p < 0.005), and between control subjects (n = 29; AUC-Cort, 150.8 ± 34.1 AU) and each patient group. Indicators of HPA axis activation correlated with neurologic disability (Kurtzkes Expanded Disability Status Scale), but not with the duration of the disease, number of previous relapses, previous corticosteroid treatments, or depressed mood (Hamilton Depression Scale). The ACTH test was normal in 31 of the 33 patients studied.
CONCLUSION: HPA axis hyperactivity in MS is related to the clinical type of disease, with a suggestion of increasing HPA axis dysregulation with disease progression.
Key words: MSHypothalamo-pituitary-adrenal axisDexamethasone-CRH test.
This article has been cited by other articles:
![]() |
D. Kos, E. Kerckhofs, G. Nagels, M.B. D'hooghe, and S. Ilsbroukx Origin of Fatigue in Multiple Sclerosis: Review of the Literature Neurorehabil Neural Repair, February 1, 2008; 22(1): 91 - 100. [Abstract] [PDF] |
||||
![]() |
C Heesen, D C Mohr, I Huitinga, F T. Bergh, J Gaab, C Otte, and S M Gold Stress regulation in multiple sclerosis-current issues and concepts Multiple Sclerosis, March 1, 2007; 13(2): 143 - 148. [Abstract] [PDF] |
||||
![]() |
L. Krupp Editorial Multiple Sclerosis, August 1, 2006; 12(4): 367 - 368. [PDF] |
||||
![]() |
J E Martinez-Rodriguez, E Munteis, and J Roquer Periodic hyperthermia and abnormal circadian temperature rhythm in a patient with multiple sclerosis Multiple Sclerosis, August 1, 2006; 12(4): 515 - 517. [Abstract] [PDF] |
||||
![]() |
C Heesen, L Nawrath, C Reich, N Bauer, K-H Schulz, and S M Gold Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 34 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Benou, Y. Wang, J. Imitola, L. VanVlerken, C. Chandras, K. P. Karalis, and S. J. Khoury Corticotropin-Releasing Hormone Contributes to the Peripheral Inflammatory Response in Experimental Autoimmune Encephalomyelitis J. Immunol., May 1, 2005; 174(9): 5407 - 5413. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Heesen, G. Koehler, R. Gross, W. Tessmer, K.-H. Schulz, and S. M Gold Altered cytokine responses to cognitive stress in multiple sclerosis patients with fatigue Multiple Sclerosis, February 1, 2005; 11(1): 51 - 57. [Abstract] [PDF] |
||||
![]() |
L. M. L. van Winsen, D. F. R. Muris, C. H. Polman, C. D. Dijkstra, T. K. van den Berg, and B. M. J. Uitdehaag Sensitivity to Glucocorticoids Is Decreased in Relapsing Remitting Multiple Sclerosis J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 734 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gottschalk, T. Kumpfel, P. Flachenecker, M. Uhr, C. Trenkwalder, F. Holsboer, and F. Weber Fatigue and Regulation of the Hypothalamo-Pituitary-Adrenal Axis in Multiple Sclerosis Arch Neurol, February 1, 2005; 62(2): 277 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. HUITINGA, Z. A. ERKUT, D. VAN BEURDEN, and D. F. SWAAB The Hypothalamo-Pituitary-Adrenal Axis in Multiple Sclerosis Ann. N.Y. Acad. Sci., May 1, 2003; 992(1): 118 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z A Erkut, E Endert, I Huitinga, and D F Swaab Cortisol is increased in postmortem cerebrospinal fluid of multiple sclerosis patients: relationship with cytokines and sepsis Multiple Sclerosis, June 1, 2002; 8(3): 229 - 236. [Abstract] [PDF] |
||||
![]() |
F. T. Bergh, T. Kümpfel, A. Grasser, R. Rupprecht, F. Holsboer, and C. Trenkwalder Combined Treatment with Corticosteroids and Moclobemide Favors Normalization of Hypothalamo-Pituitary-Adrenal Axis Dysregulation in Relapsing-Remitting Multiple Sclerosis: A Randomized, Double Blind Trial J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1610 - 1615. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |